SITE005-0020

SITE005 (FRA) › SITE005-0020

SITE005-0020

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2025-09-21

enrolled

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-24 (study day 335); relationship: NOT RELATED

mild assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 305); relationship: not assessed

moderate assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-25 (study day 244); relationship: not assessed

mild assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-02 (study day 221); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-04 (study day 70); relationship: NOT RELATED

moderate assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-04-09 (study day 14); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.